相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial
Hidehito Horinouchi et al.
ESMO OPEN (2018)
A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity
Daniel J. Crona et al.
ONCOLOGIST (2017)
Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201
Kiichiro Ninomiya et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial
K. Kubota et al.
ANNALS OF ONCOLOGY (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection
Yasuhiro Kidera et al.
PLOS ONE (2014)
Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002
Katsuyuki Hotta et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Renal Toxicity Caused by Brand-name Versus Generic Cisplatin: A Comparative Analysis
Seiji Niho et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Short Hydration in Chemotherapy Containing Cisplatin (≥ 75 mg/m2) for Patients with Lung Cancer: A Prospective Study
Hidehito Horinouchi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury
Sarah Cascaes Alves et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Use of high-dose cisplatin with aprepitant in an outpatient setting
N. Furukawa et al.
EUROPEAN JOURNAL OF CANCER CARE (2012)
Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
Fausto Petrelli et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Clinical Practice in Management of Hydration for Lung Cancer Patients Receiving Cisplatin-based Chemotherapy in Japan: A Questionnaire Survey
Kazuhiko Yamada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
Mitsue Saito et al.
LANCET ONCOLOGY (2009)
Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study
Lubomir Bodnar et al.
EUROPEAN JOURNAL OF CANCER (2008)
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
S. Burdett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
N. Pabla et al.
KIDNEY INTERNATIONAL (2008)
Cisplatin nephrotoxicity: A review
Xin Yao et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2007)
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Andrea Ardizzoni et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Y. Ohe et al.
ANNALS OF ONCOLOGY (2007)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The role of magnesium in the emergency department
P Kaye et al.
EMERGENCY MEDICINE JOURNAL (2002)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
